AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Galectin Therapeutics Inc.
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001S9NYW2
3.19▼ 0.19 (-5.62%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
3.38
Day's Range
3.16 – 3.37
52-Week Range
2.03 – 7.13
Volume
195.2K
Avg Volume
241.0K
Share Statistics
Shares Outstanding
Employees
9
Exchange
XNAS
Listed
2002-09-04
Share count as of August 6, 2026

Galectin Therapeutics Inc. (GALT) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Galectin Therapeutics Inc. (GALT)
What is Galectin Therapeutics Inc.'s Market Cap?
Galectin Therapeutics Inc.'s Market Cap is $321.7M, based on as-reported figures from SEC (XBRL) filings.
What is Galectin Therapeutics Inc.'s Enterprise Value?
Galectin Therapeutics Inc.'s Enterprise Value is $310.2M, based on as-reported figures from SEC (XBRL) filings.
What is Galectin Therapeutics Inc.'s Net Income (TTM)?
Galectin Therapeutics Inc.'s Net Income (TTM) is -$28.0M, based on as-reported figures from SEC (XBRL) filings.
What is Galectin Therapeutics Inc.'s Diluted EPS (TTM)?
Galectin Therapeutics Inc.'s Diluted EPS (TTM) is -0.28, based on as-reported figures from SEC (XBRL) filings.
What is Galectin Therapeutics Inc.'s Net Debt?
Galectin Therapeutics Inc.'s Net Debt is -$13.3M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · GALTAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses:
Research and development
General and administrative
Total operating expenses
Total operating loss
Other income (expense):
Interest income
Interest expense
Change in fair value of derivative
Total other income (expense)
Net loss
Preferred stock dividends
Net loss applicable to common stockholders
Net loss per common share — basic (in Dollars per share)
Net loss per common share — diluted (in Dollars per share)